{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:14:24Z","timestamp":1789398864036,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573534"],"award-info":[{"award-number":["82573534"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273261"],"award-info":[{"award-number":["82273261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011247","name":"State Key Laboratory of Pharmaceutical Biotechnology","doi-asserted-by":"publisher","award":["0208119002"],"award-info":[{"award-number":["0208119002"]}],"id":[{"id":"10.13039\/501100011247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011247","name":"State Key Laboratory of Pharmaceutical Biotechnology","doi-asserted-by":"publisher","award":["0208119001"],"award-info":[{"award-number":["0208119001"]}],"id":[{"id":"10.13039\/501100011247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011247","name":"State Key Laboratory of Pharmaceutical Biotechnology","doi-asserted-by":"publisher","award":["0208119004"],"award-info":[{"award-number":["0208119004"]}],"id":[{"id":"10.13039\/501100011247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108371","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:31:05Z","timestamp":1786033865000},"page":"108371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A recyclable antibody shield preserves LDL receptor homeostasis and enables durable lipid control without immune complex formation"],"prefix":"10.1016","volume":"231","author":[{"given":"Yifeng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.phrs.2026.108371_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2026.108371_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101658","article-title":"Approach to patients with elevated low-density lipoprotein cholesterol levels","volume":"37","author":"Feingold","year":"2023","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2026.108371_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"issue":"12","key":"10.1016\/j.phrs.2026.108371_bib4","first-page":"1552","article-title":"Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9","volume":"32","author":"Alkindi","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2026.108371_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/gzab032","article-title":"Modifying pH-sensitive PCSK9\/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C)","volume":"35","author":"Ben-Naim","year":"2022","journal-title":"Protein Eng. Des. Sel."},{"issue":"1","key":"10.1016\/j.phrs.2026.108371_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2575840","article-title":"IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity","volume":"17","author":"Ungan","year":"2025","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.phrs.2026.108371_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-024-00899-6","article-title":"Biodistribution of Drug\/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution","volume":"26","author":"Opolka-Hoffmann","year":"2024","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.phrs.2026.108371_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231655","article-title":"Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates","volume":"15","author":"Laffan","year":"2020","journal-title":"PLoS. One"},{"key":"10.1016\/j.phrs.2026.108371_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108371_bib10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.phrs.2026.108371_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_20_20","article-title":"PCSK9 Monoclonal Antibodies: An Overview","volume":"21","author":"Kaddoura","year":"2020","journal-title":"Heart Views"},{"issue":"9965","key":"10.1016\/j.phrs.2026.108371_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"R.-. Investigators, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2026.108371_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40262-018-0669-y","article-title":"Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I","volume":"58","author":"Martinez","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.phrs.2026.108371_bib14","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108371_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2026.108371_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cotox.2017.03.005","article-title":"Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design","volume":"4","author":"Mease","year":"2017","journal-title":"Curr. Opin. Toxicol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108371_bib17","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein convertase subtilisin\/kexin type 9 in kidney disease","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2026.108371_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-025-02274-x","article-title":"Effect of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials","volume":"86","author":"Qiao","year":"2026","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2026.108371_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12325-025-03418-x","article-title":"Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis","volume":"43","author":"Masson","year":"2026","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108371_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa2511002","article-title":"C.O.L. Investigators, A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide","volume":"394","author":"Navar","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108371_bib21","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2026.108371_bib22","first-page":"55","article-title":"The challenge to the VA health care system: portents of the FY'86 medical care budget","volume":"8","author":"Custis","year":"1985","journal-title":"J. Am. Paraplegia Soc."},{"issue":"4746","key":"10.1016\/j.phrs.2026.108371_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108371_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58069","article-title":"BLOS1 mediates kinesin switch during endosomal recycling of LDL receptor","volume":"9","author":"Zhang","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.phrs.2026.108371_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1083\/jcb.201012121","article-title":"ARH cooperates with AP-1B in the exocytosis of LDLR in polarized epithelial cells","volume":"193","author":"Kang","year":"2011","journal-title":"J. Cell. Biol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108371_bib26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"L.D.L.C.I. Open-Label Study of Long-Term Evaluation against, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.phrs.2026.108371_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"F.S. Committee, Investigators, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108371_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac028","article-title":"The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction","volume":"2","author":"Keeter","year":"2022","journal-title":"Eur. Heart J. Open."},{"issue":"14","key":"10.1016\/j.phrs.2026.108371_bib29","first-page":"915","article-title":"Beyond cholesterol","volume":"320","author":"Steinberg","year":"1989","journal-title":"Modif. Low. -Density lipoprotein that Increase Atherog. N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108371_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cells12040522","article-title":"The Role of Macrophages in the Pathogenesis of Atherosclerosis","volume":"12","author":"Blagov","year":"2023","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.phrs.2026.108371_bib31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2026.108371_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155774","article-title":"Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARalpha-mediated CYP7A1 activation","volume":"152","author":"Chen","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2026.108371_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155505","article-title":"A promising therapy for fatty liver disease: PCSK9 inhibitors","volume":"128","author":"Han","year":"2024","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.phrs.2026.108371_bib34","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301748R","article-title":"PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways","volume":"38","author":"Huang","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108371_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782788","article-title":"Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target","volume":"12","author":"Kroenke","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108371_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd7040045","article-title":"Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level","volume":"7","author":"Afanasieva","year":"2020","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2026.108371_bib37","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1002\/jps.23330","article-title":"Application of pharmacokinetics-pharmacodynamics\/clinical response modeling and simulation for biologics drug development","volume":"101","author":"Zhao","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108371_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/clinpract15100178","article-title":"Serum Sickness-Like Reaction: A Narrative Review of Epidemiology, Immunopathogenesis, Diagnostic Challenges, and Therapeutic Approaches","volume":"15","author":"Chatzigrigoriadis","year":"2025","journal-title":"Clin. Pract."},{"issue":"8","key":"10.1016\/j.phrs.2026.108371_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100248","article-title":"The small GTPase RAB10 regulates endosomal recycling of the LDL receptor and transferrin receptor in hepatocytes","volume":"63","author":"Khan","year":"2022","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108371_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13229","article-title":"Alteration in Rab11-mediated endocytic trafficking of LDL receptor contributes to angiotensin II-induced cholesterol accumulation and injury in podocytes","volume":"55","author":"Hu","year":"2022","journal-title":"Cell. Prolif."},{"issue":"1","key":"10.1016\/j.phrs.2026.108371_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s40364-024-00712-8","article-title":"PCSK9 in T-cell function and the immune response","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108371_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14728222.2025.2482545","article-title":"Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies","volume":"29","author":"Da Dalt","year":"2025","journal-title":"Expert. Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.phrs.2026.108371_bib43","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.15252\/emmm.201707672","article-title":"An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function","volume":"9","author":"Schlepckow","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2026.108371_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2017.09.034","article-title":"ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157","volume":"660","author":"Feuerbach","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2026.108371_bib45","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.neuroscience.2006.03.058","article-title":"Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: continuous shuttling to and from the plasma membrane regulated by cell stimulation","volume":"140","author":"Prada","year":"2006","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.phrs.2026.108371_bib46","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/tra.12451","article-title":"Vps35-dependent recycling of Trem2 regulates microglial function","volume":"17","author":"Yin","year":"2016","journal-title":"Traffic"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:57:14Z","timestamp":1789397834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S1043661826002860"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108371","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A recyclable antibody shield preserves LDL receptor homeostasis and enables durable lipid control without immune complex formation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108371"}}